Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Deol on the Approval of Brexucabtagene Autoleucel in MCL

September 17th 2020

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL

September 17th 2020

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Dr. Kahl on Remaining Challenges in Indolent Non-Hodgkin Lymphoma

September 17th 2020

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Dr. Maddocks on Unanswered Questions With BTK Inhibitors in B-Cell Malignancies

September 16th 2020

Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.

Dr. Burke on Treatment Options in Low-Tumor Burden Follicular Lymphoma

September 16th 2020

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

Dr. Pagel on the Evolution of Treatment in DLBCL

September 16th 2020

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

Dr. Kahl on the Current Treatment Landscape in Relapsed/Refractory iNHL

September 15th 2020

Brad S. Kahl, MD, discusses the current treatment landscape in relapsed/refractory indolent non-Hodgkin lymphoma.

Relapsed/Refractory DLBCL Paradigm Gains Chemotherapy-Free Option

September 15th 2020

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma

September 14th 2020

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness

September 11th 2020

Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.

Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies

September 11th 2020

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.

Ibrutinib Plus Rituximab Approved in Europe for Frontline CLL

September 10th 2020

The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.

Balzarotti Breaks Down New Developments in the Expanding DLBCL Paradigm

September 9th 2020

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Brody Calls for Effective Predictive Biomarker of Response to Selinexor in DLBCL

September 7th 2020

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.

FDA Approval Sought for Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

September 4th 2020

A supplemental biologics license application has been filed with the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma following 2 or more previous lines of systemic therapy.

Dr. Jacobson on the ZUMA-5 Trial With Axi-Cel in High-Risk Relapsed/Refractory iNHL

September 2nd 2020

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Dr. Maddocks on Emerging Therapies in Follicular Lymphoma

September 1st 2020

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL

August 31st 2020

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

Emerging Approaches Seek to Expand the Relapsed/Refractory Follicular Lymphoma Treatment Arsenal

August 28th 2020

Lori A. Leslie discusses several key studies evaluating emerging approaches in the relapsed/refractory follicular lymphoma paradigm.

CAR T-Cell Therapies Continue to Raise the Bar in Lymphoma Management

August 27th 2020

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.